Interferon beta-1a (Biogen)

干扰素β-1a (Biogen)

Report date: 2022/08/16 20:00:19

Base Information

Drug NameInterferon beta-1a (Biogen)
Drug Alias NameInterferon β-1a (Biogen)倍他干扰素-1a (Biogen)AvonexBG-9418IFN-B-1a +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionImmunomodulatorsInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsSpinal Cord DiseasesPolyradiculoneuropathy, Chronic Inflammatory DemyelinatingMultiple Sclerosis +[6] 
Global Approved IndicationsMultiple Sclerosis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1996/05/17
Country/TerritoryCzechiaCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPending
Originator CompaniesBiogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesBiogen Netherlands BvBiogen IncEisai Co Ltd
Inactive CompaniesNational Institute Of Neurological Disorders And StrokeNational Institute Of Allergy And Infectious Diseases (Niaid)Trio Medicines Ltd
Active IndicationsMultiple Sclerosis
Inactive IndicationsSpinal Cord DiseasesPolyradiculoneuropathy, Chronic Inflammatory DemyelinatingColitis, Ulcerative +[5] 

Other Information

ATC CodeL03AB07
Related LinksWikipediaDrugBankKEGG